Robert B. Belshe, M.D. Clinical Advisory Board Chair
Dr. Belshe is the Diana and J. Joseph Adorjan Endowed Professor of Infectious Diseases and Immunology at Saint Louis University. He is an expert in clinical trials design and execution, and his laboratory focuses on antibody responses to viral vaccines, including influenza, RSV and vaccinia. He chaired the NIH/industry cooperative Phase 3 pivotal licensing studies on live attenuated influenza vaccine, he conducted the vaccinia dilution studies for the NIH biodefense initiative and most recently he chaired the NIH and GSK Herpevac Trial for Women.
Kathleen L. Coelingh, Ph.D.
Kathleen L. Coelingh, Ph.D. was Senior Director, Medical Affairs at MedImmune, the biologics unit of AstraZeneca. Prior to that while at the NIH she led the team that discovered the mouse monoclonal antibody that neutralizes Respiratory Syncytial Virus (RSV), which was humanized at MedImmune and is licensed for prevention of serious lower respiratory tract disease caused by RSV in high-risk pediatric patients.
Harry Greenberg, M.D.
Dr. Greenberg is currently the Associate Dean for Research at Stanford University School of Medicine and the Director of Spectrum, the Stanford/NIH funded clinical and translational research center. He is also the Joseph D. Grant Professor of Medicine and Microbiology and Immunology at Stanford Medical School. He has authored more than 450 primary research and review articles and over the years has worked on a variety of pathogenic human viruses including influenza, hepatitis B and C, norovirus and rotavirus. He is a past president of the American Society of Virology, has served as the chair of the FDA Advisory Committee on Vaccines and Related Biologics, and as the Chair of the Medical Sciences Section of the AAAS. He was the Chief Scientific Officer at Medimmune Vaccines during a 2-year leave of absence from Stanford.
Yoshihiro Kawaoka, DVM, Ph.D., Co-Founder
Dr. Kawaoka has been studying influenza viruses for more than 30 years. His work has helped to answer key questions in influenza virus research such as how influenza viruses cause disease, why certain types of influenza viruses are found in humans while other types are found only in birds and how influenza viruses change over time. In 2006, Dr. Kawaoka was awarded the prestigious Robert Koch Award for his innovative research in the field of influenza virology. He currently maintains joint appointments and highly active influenza research programs at both the University of Wisconsin-Madison and the University of Tokyo.
Gabriele Neumann, Ph.D., Co-Founder
Dr. Neumann brings both significant academic and industry experiences to FluGen Inc. She is a trained molecular virologist with more than 15 years working with the influenza virus. Her graduate studies in Germany were instrumental in the breakthrough of “reverse genetics” during her postdoctoral fellowship in Dr. Kawaoka’s research group. For this accomplishment Dr. Neumann was awarded the Loeffler-Frosch Award in 2000. She also spent time in industry with Wyeth (now Pfizer) where she worked on the development of FluMistTM/ CAIV-T. In 2002, she rejoined Dr. Kawaoka’s research group, where she currently holds the position of Research Associate Professor.
John Treanor, M.D.
Dr. Treanor is an infectious disease specialist in Rochester, New York. He received his medical degree from University of Rochester School of Medicine and Dentistry and has been in practice for more than 20 years. He is the Director of the New York Influenza Center of Excellence and is a former voting member of the Advisory Committee on Immunization Practices (ACIP). Dr. Treanor serves on editorial boards and is a reviewer for multiple publications in the field of infectious diseases. He has been involved in a number of clinical studies for virtually all marketed and some novel influenza vaccines.